LRRK2 and Parkinson disease: Since we have defined specific phenotypes in fibroblasts derived from sporadic PD patients, we therefore explored whether the inhibition of LRRK2 kinase activity, a current potential therapeutic intervention, would reduce the phenotypes observed in sporadic PD patient-derived fibroblast lines.